Drug Profile
Research programme: mRNA vaccines - CureVac
Alternative Names: CV-7302; RNActive® cancer immunotherapy; RNActive® infectious disease vaccines; RNActive® prophylactic vaccinesLatest Information Update: 05 Mar 2024
Price :
$50
*
At a glance
- Originator CureVac
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Influenza A vaccines; RNA vaccines; Rotavirus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Influenza A virus infections
- Research Malaria; Rotavirus infections
- No development reported Cancer; HIV infections
- Discontinued Respiratory syncytial virus infections
Most Recent Events
- 05 Mar 2024 Early research is ongoing for Malaria, Influenza A virus infections and Rotavirus infections in Germany (CureVac pipeline, March 2024)
- 28 Jul 2023 No recent reports of development identified for preclinical development in Cancer in Germany
- 19 Jul 2023 Discontinued - Preclinical for Respiratory syncytial virus infections (Prevention) in Germany (unspecified route) (CureVac pipeline, July 2023)